Silo Pharma, Inc. Common Stock
SILOSilo Pharma, Inc. (SILO) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative and rare brain diseases. The company emphasizes leveraging its expertise in psychiatric and neurological disorders to advance innovative therapies, often through strategic partnerships and acquisitions.
Company News
Silo Pharma has initiated a strategic partnership with Fireblocks to develop an institutional-grade infrastructure for managing digital assets, leveraging Fireblocks' secure digital asset custody and transfer capabilities.
Silo Pharma announced positive results from an initial study of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia, with no serious side effects observed. The company expects final safety and absorption data in March 2025.
Silo Pharma is making progress in developing its lead assets SPC-15 and SP-26 for the treatment of PTSD, stress-induced anxiety, and chronic pain. The company is preparing to submit an IND for SPC-15 in 2025 and is advancing animal studies for SP-26 ketamine implants.
Silo Pharma, a biopharmaceutical company, has announced a $2.1 million direct offering to fund its work on novel therapies for psychiatric disorders, chronic pain, and CNS diseases. The company has made advancements in its Alzheimer's and PTSD drug development programs.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 300 points. Schlumberger reported better-than-expected second-quarter results, with revenue and adjusted EPS beating consensus estimates.
